특허 및 논문

바이오솔빅스에 자료실을 확인해 보세요.
bt_bb_section_bottom_section_coverage_image

BIOSOLVIX ARCHIVE특허 및 논문

From Bench to Market: Preparing Human Pluripotent Stem Cells Derived Cardiomyocytes for Various Applications

작성자
관리자
작성일
2024-02-01 14:40
조회
282
Moon SH, Bae D, Jung TH, Chug EB, Jeong YH, Park SJ, Chung HM*. From Bench toMarket: Preparing Human Pluripotent Stem Cells Derived Cardiomyocytes for Various Applications. Int J Stem Cells. 2017 May 30;10(1):1-11. doi: 10.15283/ijsc17024. Review.

Abstract

Human cardiomyocytes (CMs) cease to proliferate and remain terminally differentiated thereafter, when humans reach the mid-20s. Thus, any damages sustained by myocardium tissue are irreversible, and they require medical interventions to regain functionality. To date, new surgical procedures and drugs have been developed, albeit with limited success, to treat various heart diseases including myocardial infarction. Hence, there is a pressing need to develop more effective treatment methods to address the increasing mortality rate of the heart diseases. Functional CMs are not only an important in vitro cellular tool to model various types of heart diseases for drug development, but they are also a promising therapeutic agent for cell therapy. However, the limited proliferative capacity entails difficulties in acquiring functional CMs in the scale that is required for pathological studies and cell therapy development. Stem cells, human pluripotent stem cells (hPSCs) in particular, have been considered as an unlimited cellular source for providing functional CMs for various applications. Notable progress has already been made: the first clinical trials of hPSCs derived CMs (hPSC-CMs) for treating myocardial infarction was approved in 2015, and their potential use in disease modeling and drug discovery is being fully explored. This concise review gives an account of current development of differentiation, purification and maturation techniques for hPSC-CMs, and their application in cell therapy development and pharmaceutical industries will be discussed with the latest experimental evidence.

Keywords : #Human pluripotent stem cell #Cardiomyocytes #Cell therapy #Drug discovery #Disease modeling

논문확인(클릭시 이동)
전체 52
번호 제목 작성자 작성일 추천 조회
32
Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infraction.
관리자 | 2024.02.01 | 추천 0 | 조회 211
관리자 2024.02.01 0 211
31
Functional Equivalency in Human Somatic Cell Nuclear Transfer-Derived Endothelial Cells.
관리자 | 2024.02.01 | 추천 0 | 조회 216
관리자 2024.02.01 0 216
30
Reconstituting human cutaneous regeneration in humanized mice under endothelial cell therapy.
관리자 | 2024.02.01 | 추천 0 | 조회 270
관리자 2024.02.01 0 270
29
Safety and Optimization of Metabolic Labeling of Endothelial Progenitor Cells for Tracking
관리자 | 2024.02.01 | 추천 0 | 조회 215
관리자 2024.02.01 0 215
28
Mechanotransduction of human pluripotent stem cells cultivated on tunable cell-derived extracellular matrix.
관리자 | 2024.02.01 | 추천 0 | 조회 211
관리자 2024.02.01 0 211
27
Angiogenesis in the Transplanted Donor Graft After Living-Donor Liver Transplantation.
관리자 | 2024.02.01 | 추천 0 | 조회 259
관리자 2024.02.01 0 259
26
From Bench to Market: Preparing Human Pluripotent Stem Cells Derived Cardiomyocytes for Various Applications
관리자 | 2024.02.01 | 추천 0 | 조회 282
관리자 2024.02.01 0 282
25
Enzyme catalyzed electrostimulation of human embryonic stem cell-derived cardiomyocytes influence contractility and synchroniza
관리자 | 2024.02.01 | 추천 0 | 조회 236
관리자 2024.02.01 0 236
24
Metabolome Profiling of Partial and Fully Reprogrammed Induced Pluripotent Stem Cells.
관리자 | 2024.02.01 | 추천 0 | 조회 321
관리자 2024.02.01 0 321
23
Effect of BMP-2 Delivery Mode on Osteogenic Differentiation of Stem Cells.
관리자 | 2024.02.01 | 추천 0 | 조회 270
관리자 2024.02.01 0 270